Table 5.
Results of the cost–utility analysis.
| Results of the Cost-Utility Analysis | Dupilumab + BSC (A) |
BSC (B) |
Difference (A−B) |
|---|---|---|---|
| Outcome | |||
| Years of life adjusted for quality (QALYs) | 17.15 | 16.13 | 1.02 |
| Direct costs (€) | |||
| Drug acquisition costs | €76,383 | €0 | €76,383 |
| Disease management costs * | €275,517 | €329,367 | −€53,850 |
| Adverse events costs | €1083 | €1333 | −€249 |
| TOTAL direct costs | €352,983 | €330,700 | €22,283 |
| Incremental cost–utility ratio (ICUR) | |||
| ICUR (dupilumab vs. BSC) (€/QALY) | €21,817 | ||
Note: * They include the costs of surgery. BSC: best supportive care; ICUR: incremental cost–utility ratio; QALY: quality adjusted life year.